Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1992-03-18
1998-02-10
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514315, 514468, 514654, 514913, A61K 3155, A61K 31445, A61K 3134, A61K 31135
Patent
active
057169527
ABSTRACT:
Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more muscarinic antagonist compounds. Examples of muscarinic antagonists utilized in the pharmaceutical composition and method of treatment are: 10H-thieno(3,4-b)(1,5)benzodiazepin-10-one 4,9-dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl) (telenzepine); zodiazepin-6-one (pirenzepine); racemic salt of 4-diphenylacetoxy-1,1-dimethyl piperidine (4-DAMP); .alpha.-cyclohexyl, -.alpha.-phenyl-1-piperidinepropanol (trihexyphenidyl); cyclohexanemethanol, .alpha.-phenyl, monomethanesulfonate (AF-DX 384); 1,8-octanediamine, .alpha.!!(himbacine).
REFERENCES:
patent: 2918407 (1959-12-01), Biel
patent: 3467756 (1969-09-01), Stone
patent: 3743734 (1973-07-01), Schmidt et al.
patent: 4197301 (1980-04-01), Smith et al.
patent: 4550107 (1985-10-01), Engel et al.
patent: 4556653 (1985-12-01), Giani et al.
patent: 4565821 (1986-01-01), Chiou
patent: 4886815 (1989-12-01), Schachar
patent: 4971966 (1990-11-01), Engel et al.
patent: 5066664 (1991-11-01), Gluchowski
patent: 5091528 (1992-02-01), Gluchowski
Embase Abstract of Invest. Ophthalmol., Visual Science. (USA), 1980. Bito et al.
Chemical Abstract, 13: 108137d (1988) Hagan et al.
J.A. Pino Capote, British Journal of Anesthesia, vol. 50, No. 8 1978, p. 865.
Archives Of Pharmacology, vol. 338, No. 5, 1988, pp. 476-483, J. J. Hagan et al., `The Relative Potencies of Colinominetics and Muscarinic Antagonists on the Rat Iris in Vivo: Effects of PH on Potency of Pirenzepine and Telenzepine`.
Current Eye Research, vol. 3, No. 8, 1984, pp. 1001-1006 P.C.M. Van Pinxteren et al. `Acetylcholine Can Exert Two Opposite Effects on Uveal Flow in Isolated Arterially Perfused Eyes of Cats and Rabbits`.
Therapie, vol. 43, No. 3, 1988, pp. 219-228, C. Giraud et al. `Medicaments A Potentiel Anticholinergigue`.
E.C. Hulme et al., Muscarinic Receptor Subtypes, Annu. Rev. Pharmacol Toxicol, (1990), 30 633-73.
W. Londong, et al., Telenzepine is at least 25 times more potent than pirenzepine--a dose response and comparative secretory study in man, Gut, 1987, 28, 888-895.
Dammann, et al., AF-DX 116 differentiates between prejunctional muscarine receptors located on noradrenergic and cholinergic nerves, Archives of Pharmacology, (1989) 339:268-271.
S. Anwar-ul, et al., The cardio-selectivity of himbacine: a muscarine receptor antagonist, Archives of Pharmacology, (1986).
Carlo Melchiorre, et al., Differential Blockade of Muscarinic Receptor Subtypes by Polymethylene Tetraamines. Novel Class of Selective Antagonists of Cardiac M-2 Muscarinic Receptors, J. Med. Chem. (1987) 30, 201-204. methyl hexylamino!-1,8-octanediamine (methoctramine), Chemistry & Industry 2 Oct. 1989, pp. 652-653.
Stephen B. Coan, et al., Parasympathetic Blocking Agents, II, The Journal of Organic Chemistry, Jun. 1955, vol. 20, pp. 774-779.
Ruiz Guadalupe
WoldeMussie Elizabeth
Allergan
Baran Robert J.
Fay Zohreh
Szekeres Gabor L.
Voet Martin A.
LandOfFree
Method for reducing intraocular pressure in the mammalian eye by does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing intraocular pressure in the mammalian eye by, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing intraocular pressure in the mammalian eye by will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2077522